|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| The Effects of Vibegron on Ambulatory Blood Pressure in Patients With Overactive Bladder |
| Michael A. Weber, MD |
| Diane Newman is joined by Michael Weber discussing a novel medication for the treatment of overactive bladder and a study Dr. Weber presented at the AUA 2021 Annual Meeting. |
|
|
|
|
|
|
|
|
|
|
|
|
Advancements in Pharmacological and Device-Based OAB Treatment Options
|
|
Eric S. Rovner, MD
|
| Joining Thomas Keane to discuss the various advancements, both present and upcoming, in the field of overactive bladder treatment is Eric Rover. Dr. Rovner highlights advances in both office-based treatments, pharmacologic treatments, and surgery, as well as emerging new technologies specific to sacral neuromodulation as well as developments in the world of chemodenervation specific to Botox® for OAB.
|
|
|
|
|
|
|
|
|
|
|
|
| The OAB Clinical Care Pathway Mobile APP |
| Stephen R. Kraus, MD, MBA, FACS |
| In this informational video presentation, Stephen Kraus provides an update on the SUFU overactive bladder (OAB) Clinical Care Pathway as a dissemination effort to broadcast the advantages of the pathway for both physicians and patients. |
|
|
|
|
|
|
|
|
|
|
|
| Overactive Bladder (OAB) and Urinary Incontinence Clinical Care Pathway
|
| Diane Newman, DNP, ANP-BC, FAAN
|
| Overactive bladder (OAB) is a symptom complex of lower urinary tract symptoms of urgency, and frequency with or without urinary incontinence. It is prevalent in both men and women. Diane Newman discusses effective treatments including newly approved medications, and the AUA treatment guideline for OAB.
|
|
|
|
|
|
| The Prevalence of Antimicrobial Resistant Pathogens Causing Recurrent Urinary Tract Infections Amongst Female Patients in an Outpatient Female Pelvic Medicine Practice in the NY/NJ Metropolitan Area |
| Marcus Cunningham, Barry N. Kreiswirth, Claudia Manca, Barun Mathema, Jared Benjamin |
| This was a retrospective cross-sectional study to examine the clinical and microbiological properties of all women with culture-confirmed singular or sporadic urinary tract infections (sUTI) compared to those with recurrent UTIs (rUTI) in an outpatient female urology practice. |
|
|
|
|
|
|
|
|
|
|
| Trends In Diagnostic Workup and Surgical Management For Recurrent Urinary Tract Infections
|
| Victoria Edmonds, BS
|
| There is variability in the evaluation, treatment, and referral patterns for recurrent urinary tract infections (rUTI). This group sought to analyze patterns in the workup and surgical management of rUTIs at their institution. Data collected included demographics, provider specialty, and workup, including the performance of genitourinary exam, urodynamic evaluation, cystoscopy, imaging, and if the patient underwent a surgical procedure and type.
|
|
|
|
|
|
| Toileting Behaviors in Adult Women with Recurrent Urinary Tract Infections in a Large Cross Sectional Survey Study
|
| Elisabeth Sebesta, MD, Elizabeth Rourke, MD, Casey Kowalik, MD, Melissa Kaufman, MD, Roger Dmochowski, MD, W. Stuart Reynolds MD
|
| The aim of this secondary analysis was to assess whether women with recurrent urinary tract infections (rUTIs) report more unhealthy bladder and bowel habits. The sample was 6,074 non-institutionalized, adult U.S. women recruited through online ResearchMatch. Women completed validated questionnaires assessing demographic and clinical history, toileting behaviors (TB-WEB), urinary symptoms (ICIQ-FLUTS), and bowel habits (ICIQ-BS). Subjects were excluded if they were pregnant, used a urinary catheter, or had a history of cystectomy, neurogenic bladder, or neurological disorder.
|
|
|
|
|
|
| Social Media Analytics of Overactive Bladder Posts: What do Patients Know and Want to Know? - Beyond the Abstract
|
| Gabriela Gonzalez, MD, MPH and Jennifer T. Anger, MD, MPH
|
| To date, research has focused less on prevention of lower urinary tract symptoms (LUTS) and more on identifying causes and phenotypes of LUTS. The impact of behavioral, psychological, and socioeconomic contributors to LUTS is understudied. To identify strategies for promoting bladder health and reducing LUTS in women, the National Institute of Diabetes and Digestive and Kidney Diseases supported the development of the Prevention of Lower Urinary Tract Symptoms (PLUS) Consortium.
|
|
|
|
|
|
| Outcomes of a Single Trigone-Only vs. 20 Trigone-Sparing Injections of OnabotulinumtoxinA for Refractory Overactive Bladder (OAB) - Beyond the Abstract
|
| Eboo Versi, MD, Ph.D.
|
| To compare the safety and durability of a single intravesical trigonal-only versus 20 trigone-sparing injections of OnabotulinumtoxinA (BTA) for refractory OAB, a chart review of all idiopathic OAB patients treated with BTA from January 2016 to December 2018 was performed. Outcomes measures included: inter-injection interval, post-void residual (PVR), urinary tract infections (UTI), urinary retention requiring catheterization, and procedure time (min). Statistical analyses were performed using independent sample t-tests.
|
|
|
|
|
|
|
|
|
|
|
|
